跳至主要内容
临床试验/NCT00911196
NCT00911196已完成不适用

Analysis of the Incidence of Expression of Tumor Antigens and Tumor Marker in Cancer Tissue From Asian Patients With Hepatocellular Carcinoma and Evaluation of Prognostic Significance of These Tumor Antigens.

GlaxoSmithKline1 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2008年11月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
200
试验地点
1
主要终点
The prognostic character of the expression of the tumor antigens

研究概览

简要总结

Hepatocellular carcinoma is an aggressive disease with limited therapeutic options. Therefore, new approaches to treat this type of cancer are needed with immunotherapy potentially being one of these. As a first step in the development of novel therapies, expression analysis of specific markers, including tumor antigens will be carried out, and the correlation of expression with disease variables and clinical outcome will be assessed. This will be done retrospectively using archived hepatocellular carcinoma tissue samples.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Retrospective

入排标准

性别
All
接受健康志愿者

入选标准

  • The patient has pathologically proven hepatocellular carcinoma (any stage)
  • All the data required are available from patient's records

排除标准

  • 未提供

结局指标

主要结局

The prognostic character of the expression of the tumor antigens

时间窗: At the time of analysis

Expression of c-MET in the same hepatocellular carcinoma tumor samples

时间窗: At the time of analysis

The proportion of hepatocellular carcinoma patients whose tumor tissue expresses specific tumor antigens.

时间窗: At the time of analysis

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验